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Lysosomal storage diseases (LSDs) is a group consisting of over 50 disorders caused mostly by dysfunctions of lysosomal proteins and resultant accumulation of particular compounds inside cells and extracellular volumes in affected organisms. Genetic diseases are among the most difficult targets for medical treatment. Nevertheless, understanding of molecular bases of LSDs made it possible to develop novel procedures of treatment, employing molecular medicine. Although various therapeutic approaches have been proposed, and some of them were introduced into clinical practice, none of them was found to be effective in correcting all symptoms in treated patients. Central nervous system and skeleton appear to be the most difficult targets to be improved. Therefore, a proposal appeared that perhaps no single therapeutic procedure may be fully effective in treatment of LSD patients, and only combination of two or more approaches could be a successful therapy. In this review, we present and discuss current stage of various combination therapies for LSDs, based on already available published data.













Introduction: lysosomal storage diseases and therapeutic options
Although currently vast majority of genetic diseases cannot be effectively treated, several therapeutic options are available for lysosomal storage diseases (LSDs), a group of inherited metabolic disorders, and other treatment procedures are under development [1-5]. This privileged position of LSDs stems from our understanding of molecular mechanisms of these diseases and availability of various research models, both cellular and animal, which allowed researchers to conduct extensive studies on various potential methods of treatment [6-13]. Therefore, despite the fact that mechanisms of LSDs appeared significantly more complicated than initially supposed [14] specific therapies for some LSDs are in clinical practice now [1]. Because of the nature of LSDs, most of newly developed therapies for these diseases, or those being under development, are based on molecular medicine. 
The primary mechanisms of LSDs are based on mutations in certain genes coding for proteins involved in lysosomal functions (note that each particular LSD is a monogenic disorder). A lack or severe impairment of activity of particular protein causes dysfunction of lysosomal apparatus and accumulation of certain compound(s) in lysosomes. This is the first step of the cascade of secondary effects leading to different perturbations in cellular metabolism, followed by dysfunctions of tissues and organs. LSDs are classified according to the kind of deficient protein and nature of primarily accumulated compound(s) [15]. The mechanisms of LSDs are presented schematically in Fig. 1.
LSDs are recognized as severe diseases, characterized by high morbidity and mortality, with average life span below two decades. In most diseases from this group, central nervous system (CNS) is affected, which makes them particularly difficult to manage [16]. However, several medical products have been approved for use in treatment of different LSDs, and some of them were found relatively effective in treatment of somatic symptoms [17]. On the other hand, no currently used treatment can correct all disease symptoms. Moreover, none is effective in management of neuronopathy in patients [1]. Therefore, a proposal appeared that perhaps no single therapeutic procedure may be fully effective in treatment of LSD patients, and only combination of two or more approaches could be a successful therapy [18-21]. The most important therapies either already used to treat LSD patients or being under development are listed in Table 1.  
In this review, we present and discuss the current stage of development of various therapeutic approaches, with special emphasis on experiments with a combined use of more than one treatment at the time. Particular LSDs or subgroups of them will be discussed sequentially to underline specificity of each disease or a subgroup of disorders.

Gaucher disease
Gaucher disease (GD) is caused by mutations in the GBA gene, coding for lysosomal glucocerebrosidase, and resultant accumulation of glucosylceramide and glucosylsphingosine. Currently there are two different therapeutic approaches approved for GD, one based on enzyme replacement therapy (ERT) and the other on substrate reduction therapy (SRT). ERT with imiglucerase (Cerezyme; Genzyme Corporation), velaglucerase alpha (VPRIV; Shire HGT) or taliglucerase alpha (Elelyso; Pfizer and Protalix BioTherapeutics) corrects disease manifestations in visceral organs and haematological parameters, but fails to manage neurological symptoms in neuronopathic types of GD (type 2 and 3). An approved SRT for Gaucher disease is based on oral administration of N-butyldeoxynojirimycin (NB-DNJ, miglustat, Zavesca; Actelion Pharmaceuticals), an iminosugar acting as an inhibitor of glucosylceramide biosynthesis by reversible inhibition of glucosylceramide synthase activity. Miglustat has been shown to improve clinical features in patients with GD type 1 (non-neuronopathic) with mild to moderated symptoms who are unable to be treated with ERT (reviewed in [22]). Some other therapeutic strategies for Gaucher disease are tested in vitro or are a subject of clinical trials, e.g. SRT with eliglustat tartrate, that is another glucosylceramide synthase inhibitor [23], or therapies with drugs acting as pharmacological chaperones (PC) for glucocerebrosidase such as isofagomine (IFG) [24, 25] and ambroxol (to date, commonly used as a mucolytic drug) [26, 27].
Several studies described also effects of different combination therapies for GD using cell cultures, animal models as well as studies on humans.  A case of an adult white male Gaucher disease type 3 patient was described, who received ERT alone for several years, and next SRT with miglustat was included in the treatment together with imiglucerase [28]. During the ERT treatment, started at the age of 18, first with alglucerase, then continued with imiglucerase combined with anticonvulsant drugs, visceral and hematological parameters markedly improved, but the neurological deterioration and epileptic manifestation progressed. Next, during twoyears of combination therapy with miglustat and imiglucerase, an improvement of the neurological outcome of the disease has been reported, especially regarding the epilepsy events and speech as symptoms of the neuropathology [28]. On the contrary, 24-month, phase II, open-label clinical trial conducted on type 3 Gaucher disease patients revealed no effect of miglustat treatment combined with ERT on neurological manifestations of the disease [29]. Nevertheless, some positive effects on systemic disease were observed during the trial, including improvement in pulmonary function and decrease in chitotriosidase activity [29]. On the other hand, the case of three siblings with type 3 Gaucher disease treated with ERT combined with SRT was reported  [30]. Treatment with high-dose imiglucerase (120 U/kg) together with miglustat, started at the age of 5 months in the youngest sibling, resulted in complete neurological stabilization and age-appropriated psychomotor development in that patient after two years of combination therapy. Although including miglustat to high-dose ERT treatment of two elder siblings (at the age of 14 and 10 years), who were already severely developmentally delayed, did not improve the neurological status, it remained stable and no further deterioration was observed after two years of combination treatment. Additionally, chitotriosidase activity in cerebrospinal fluid was not elevated after 1.5 year of combination treatment comparing to the baseline. These results suggested that this kind of therapeutic approach, based on combination of ERT and SRT with miglustat, might prevent neurodegeneration in GD type 3 [30].
In another clinical trial, the safety and efficacy of miglustat treatment was tested in Gaucher disease type 1 patients, first stabilized with imiglucerase and next switched to miglustat monotherapy or to combination therapy with miglustat and intravenous enzyme replacement [31]. After 6 months of treatment, clinical parameters of Gaucher disease type 1 were stable in most patients switched to miglustat, comparing to the group continuing imiglucerase monotherapy. However, combination therapy (miglustat with imiglucerase) did not show any additional benefit comparing to both monotherapies. Miglustat was shown to be well tolerated either alone or in combination with imiglucerase [31]. Similar results (i.e. no change in liver volume) of miglustat monotherapy during 24 months after switch from previous ERT, were obtained, suggesting that miglustat could maintain clinical stability (ClinicalTrials.gov identifier: NCT00319046) [32]. Haematological and organ volume stability was also obtained in GD type 1 adult patients first stabilized with imiglucerase ERT and switched to oral eliglustat tartrate (another inhibitor of glucosylceramide synthase) for 12 months of treatment (ClinicalTrials.gov identifier: NCT00943111) [33]. 
Miglustat has been shown to act not only as an inhibitor of glucosylceramide biosynthesis (in SRT) but also as a pharmacological chaperone towards some mutant variants of glucocerebrosidase in cell culture studies [34]. It was demonstrated that miglustat binds to both glucocerebrosidase forms available in ERT (i.e. imiglucerase and velaglucerase alfa) in neutral pH conditions, enhancing the stability of both enzymatic preparations in vitro(35). Results of biochemical studies supported the hypothesis that this compound acts as a pharmacological chaperone for the enzyme. Enzyme-miglustat binding has been shown to be pH-dependent, i.e. in neutral pH, miglustat slightly stabilized the enzyme, but it dissociated at the acidic pH present in the lysosomal compartment (at pH of 5), thus, it suggested the protective role of miglustat on enzyme degradation, which may occur in blood and cytosol after administration. Thus, miglustat was proposed to be used as a part of the enzyme formulation or as a part of combination therapy for Gaucher disease, performing as a pharmacological chaperone for the enzyme protein [35]. 
Another iminosugar, isofagomine was shown to act as a pharmacological chaperone that in monotherapy stabilizes and enhances mutant glucocerebrosidase activity in cell cultures [25]. This potential therapeutic agent was also studied in combination with ERT for Gaucher disease. IFG was shown to stabilize exogenous imiglucerase in vitro, acting as a pharmacological chaperone In experiments with cultured macrophages, the intracellular uptake and catalytic activity of exogenous imiglucerase were elevated, and degradation of the enzyme after cellular internalisation was decreased if the enzyme was first preincubated with IFG, as compared to untreated enzyme. IFG was also shown to protect imiglucerase from denaturation by heat, neutral and mildly-alkaline pH, as well as chemical denaturant such as SDS [36]. 
In 2012,  during the 8th Annual Lysosomal Disease Network WORLD Symposium, a pharmaceutical company Amicus Therapeutics, presented results of preclinical studies of small molecule pharmacological chaperone AT3375 (an improved compound of isofagomine tartrate, AT2101) as a monotherapy and in combination with ERT for Gaucher disease [37]. They demonstrated in vitro stabilization of the recombinant enzyme as well as increased uptake of the active enzyme in disease-affected tissues (as liver, spleen and lung) upon co-administration with AT3375. These results supported the idea that the combination therapy based on co-administration of pharmacological chaperone and enzyme has a great potential to improve the properties of ERT for Gaucher disease.
Another study showed that co-administration of the pharmacological chaperone N-(n-Nonyl)-1-deoxynojirimycin (also called NN-DNJ), together with celastrol (a triterpenoid compound,  potent antioxidant and immunosuppressant) or with MG132 (N-[(Phenylmethoxy)carbonyl]-L-leucy​l-N-[(1S)-1-formyl-3-methylbutyl]-L-leucinamide), demonstrated to act as proteostasis regulators, and resulted in higher enhancement of the activity of two glucocerebrosidase mutant variants (G202R and L444P) in GD fibroblast cultures, compared to cell cultures treated with celastrol or MG132 as a monotherapy [38]. The authors demonstrated that the treatment of fibroblasts with celastrol and MG132 activates the heat-shock response and unfolded protein response pathways and results in decreased intracellular misfolding and aggregation of mutant enzyme molecules [38]. These results also supported their hypothesis that the action of pharmacological chaperone molecules (such as NN-DNJ), in combination treatment, may stabilize the folded mutant enzyme, and thus increase its proper transport to the lysosomal compartment. Moreover, recent studies indicated that celastrol and MG132 improved folding of L444P mutant glucocerebrosidase expressed in plant cells, corroborating the above hypothesis [39].
Recent studies on GD fibroblasts with L444P mutation (associated with neurological forms of GD) demonstrated that a combination of coenzyme Q10 (CoQ) supplementation together with pharmacological chaperone N-[N’-(4-adamantan-1-ylcarboxamidobutyl)thiocarbamoyl]-1,6-anhydro-L-idonojirimycin (NAdBT-AIJ, a derivative of L-idonojirimycin) improved mitochondrial dysfunction observed in case of L444P mutation as well as increased β-glucocerebrosidase activity [40]. Combination of both, CoQ and NAdBT-AIJ, significantly increased mitochondrial membrane potential and cellular ATP levels, cell proliferation rate, markedly decreased reactive oxygen species levels in cell cultures, normalized autophagic proteins expression and increased mitochondrial protein expression nearly to control cell levels as compared to untreated GD cells or cells treated with each of these agents alone. The combined CoQ and NAdBT-AIJ treatment not only increased activity of the cellular glucocerebrosidase, but also improved the trafficking of the enzyme to lysosomes and the combined treatment resulted in decreased glucosylceramide accumulation in cultured GD fibroblasts.

Fabry disease
Fabry disease (FD) is characterized by lysosomal storage of globotriaosylceramide (Gb3, GL-3). Accumulation of this compound results from dysfunction of α-galactosidase A (α-Gal A), encoded by the GLA gene, located on the X chromosome. Major symptoms are progressive renal failure, cardiac disease, cerebrovascular problems, small-fiber peripheral neuropathy, and angiokeratoma skin lesions [41]. The only currently approved treatment for Fabry disease is enzyme replacement therapy providing exogenous replacement of the deficient  enzyme. Although many characteristics of the disease in Fabry patients appear to be responding well to ERT, it has limited effectiveness and there is certainly a need for better and more affordable treatments [42].
Substrate reduction therapy, proposed for Fabry disease, uses inhibitors of glucosylceramide synthase which catalyzes the first step in the synthesis of glycosphingolipids (GL-1), limiting the production of subsequent molecules including GL-3 [43]. It was pointed out that since majority of male Fabry patients are null for α-Gal A activity, SRT is unlikely to be effective treatment as a monotherapy for them and that combination of ERT and SRT may be a more beneficial approach to managing Fabry disease [43]. The authors also demonstrated, using a Fabry mouse model, that the therapeutic benefit of the combined therapy approach is both additive and complementary for treating this disease and that it can bring a treatment option allowing for a reduced frequency of ERT while on SRT maintenance therapy, improving quality of life through a reduced dependency on enzyme infusions [43].
An alternative treatment, pharmacological chaperone therapy with an active-site-speciﬁc chaperone, such as the catalytic product galactose [44], or a product analog, such as the iminosugar 1-deoxygalactonojirimycin (DGJ, migalastat-hydrochloride, AT1001, GR181413A) has been proposed for Fabry disease [45]. Guce at el. examined the biochemical and biophysical basis for both PCs binding to human α-Gal A and showed that DGJ, which is only two functional groups different from galactose, binds to and stabilizes α-Gal A with higher potency [46]. Additionally, since DGJ has a 120,000-fold greater aﬃnity for human α-Gal A, it can be given orally, and for this route of administration it has successfully completed phase 2 clinical trials [47]. A randomized, open-label study to compare the efficacy and safety of oral AT1001 and ERT in male and female patients with Fabry disease who are currently receiving ERT, and who have AT1001-responisive α-Gal A mutations, started at the end of 2010 and was completed on May 2015, with no published results up to date (ClinicalTrials.gov Identifier: NCT01218659).
The enhancing effect of DGJ on endogenous α-Gal A in fibroblasts from a patient with Fabry disease, with a two-fold increase from baseline activity has been confirmed [48]. It was also observed that partially corrected enzyme activity obtained in these cells after incubation with recombinant α-Gal A (3.8-fold increase from baseline) was almost 9 times higher in the presence of DGJ [48]. 
The synergistic effect between ERT and PC therapy was also proved in Fabry disease fibroblasts with negligible residual enzyme activity [49], as well as in rats and α-Gal A knockout mice [50]. In the later studies, co-administration of DGJ with the recombinant α-Gal A resulted in prolonged half-life of the enzyme in the circulation, increased enzyme activity in cells and greater Gb3 reduction in tissues compared to that seen with ERT alone [51]. Based on these encouraging findings, phase 2 clinical investigations entitled Drug-Drug Interaction Study Between AT1001 and Agalsidase in Subjects With Fabry disease (ClinicalTrials.gov Identifier: NCT01196871) have been initiated. Preliminary results showed that single doses of 150 mg and 450 mg AT1001 with agalsidase (ERT) doses of 0.2 mg/kg, 0.5 mg/kg, and 1.0 mg/kg increased active plasma α-Gal A AUC levels by 1.2- to 5.0-fold in 22 out of 23 Fabry patients (95.7%) relative to agalsidase administered alone [52]. Amicus Therapeutics is leveraging the Chaperone-Advanced Replacement Therapy (CHART™) platform to develop AT-B100 (also known as JR-051), a proprietary investigational recombinant human α-Gal enzyme, co-formulated with migalastat HCl (http://www.amicusrx.com/fabry.aspx). 
An alternative therapy has been also proposed recently. It was reported that both ambroxol (a mucolytic and expectorant drug) and rosiglitazone (to date, used as an antidiabetic drug) act as enhancers of pharmacological chaperones such as 1-deoxygalactonojirimycin and, when co-administrated, improve the activity of the mutant α-galactosidase, thus, both drugs might be considered as potent enhancers of FD treatment strategies [53].
Palliative and symptom specific measures, such as stroke prophylaxis, pacemaker insertion, dialysis, and kidney transplantation still play an important role in managing Fabry disease. The benefit of ERT in dialysis or kidney transplanted Fabry patients has been controversially discussed and long-term trials focusing on the effectiveness of agalsidase in this patient population are needed [54, 55]. Sanofi company proposed phase 4 clinical studies designed to verify that no loss of Fabrazyme occurs during simultaneous Fabrazyme infusion and hemodialysis (ClinicalTrials.gov Identifier: NCT00312767), but the study has been withdrawn prior to enrollment.

Pompe disease
Pompe disease (PD) is a metabolic myopathy, caused by the deficiency of a lysosomal enzyme acid-alpha-glucosidase (GAA). The consequence of GAA deficiency is muscle inflammation, disruption of muscle tissue, and impaired function of heart and skeletal muscle. At present, a specific treatment is available for PD, enzyme replacement therapy, based on the periodic intravenous infusion of recombinant human GAA (rhGAA). However, ERT, although successful in reverting cardiac involvement and improving muscle function in some patients, has limitations. Specifically, correction of the enzyme defect and of function in skeletal muscle is insufficient in several patients. Several factors contribute to the resistance of skeletal muscle to ERT. These include the sheer mass of muscle tissue, a relatively low density of the mannose-6-phosphate (M6P) receptor, inefficient trafficking of the internalized enzyme to lysosomes, immune response to the recombinant enzyme in cross-reactive immunologic material (CRIM)-negative patients, and the presence of large areas of autophagic build-up alongside expanded lysosomes [56-59].
Pompe-affected children who do not express endogenous GAA and undergo myozyme treatment develop high-titer anti-drug-antibodies (ADA) because they are not immunologically tolerant to acid-alpha-glucosidase. Significant efforts are aimed at improving the current therapy, such as the development of "second generation" recombinant enzymes with enhanced targeting properties [60, 61], pharmacological chaperones that assist the folding of the mutant enzyme [62, 63] or increase the stability of the recombinant enzyme [48, 64], and gene therapy [65] or combination of these approaches.
A general strategy for lysosomal storage disorders, among them Pompe disease, is to search for small pharmacological chaperones that are able to bind the active site of mutant enzymes and to facilitate the folding and transport process. These molecules have the ability to improve the trafficking of the mutant protein between the endoplasmic reticulum (ER) and the lysosome, resulting in phenotypic correction. 1-deoxynojirimycin (DNJ) and N-butyl-DNJ were investigated in fibroblasts from Pompe patients [48, 62]. A significant increase of acid-alpha-glucosidase activity was observed in fibroblasts from patients carrying different GAA mutations such as L552P, G549R, Y445F, and P545L. Furthermore, a synergistic effect of N-butyl-DNJ and rhGAA was observed in Pompe disease fibroblasts, resulting in a higher enzymatic correction due to an improved enzyme maturation and delivery to the lysosome [48]. Recent preclinical studies with 13 PD patients demonstrated that the pharmacological chaperone, N-butyldeoxynojirimycin, significantly stabilized the recombinant enzyme used for ERT, while it was given to the patients at the time of enzyme infusion [66]. The activity of α-glucosidase detected in the blood was significantly higher up to 36 hours after administration when patients were infused with the combination of the enzyme and the chaperone (up to 6-fold increase after 24 hours) as compared to the activity of the enzyme when it was infused alone and the AUC values were reported to be almost 7-fold higher for the enzyme in combination treatment [66]. Other studies demonstrated that in Pompe disease, similar to Fabry disease, co-administration of ambroxol enhanced the action of pharmacological chaperone such as 1-deoxygalactonojirimycin, and the combination of these drugs increased the activity of mutant acid α-glucosidase [53].
A novel series of noniminosugar chaperones for GAA were identified. These moderate acid-alpha-glucosidase inhibitors are shown to bind and thermostabilize the enzyme and increase GAA translocation to lysosomes in both wild-type and Pompe fibroblasts [67]. N-acetylcysteine (NAC) is an allosteric chaperone for alpha-glucosidase. NAC improved the stability of rhGAA as a function of pH and temperature without disrupting its catalytic activity. NAC enhanced rhGAA efficacy and the residual activity of mutated acid-alpha-glucosidase in cultured PD fibroblasts. In cells incubated with NAC and rhGAA, acid-alpha-glucosidase activities were 3.7-8.7-fold higher than those obtained in cells treated with rhGAA alone. In a PD mouse model the combination of NAC and rhGAA resulted in better correction of enzyme activity in liver, heart, diaphragm and gastrocnemia, compared to rhGAA alone [64].
Amicus is leveraging its Chaperone-Advanced Replacement Therapy platform in combination with a uniquely-engineered, proprietary rhGAA (designated AT-B200) to develop a next-generation ERT for Pompe disease. AT-B200 has significantly higher amounts of mannose 6-phosphate carbohydrates which may enable better drug targeting than existing Pompe ERTs. In preclinical studies, AT-B200 was shown to have superior uptake and activity in disease-relevant tissues that correlated with clearance of accumulated glycogen substrate when compared to current standard of care. AT-B200 may be further improved through the application of the company’s proprietary conjugation technology to attach vIGF2 (a variant of the insulin growth factor 2 receptor) to further enhance drug targeting. The vIGF2 peptide binds the intended IGF2 receptor, but does not bind to insulin or the IGF1 receptor. 
Co-formulating AT-B200 with the pharmacological chaperone AT2220 (duvoglustat HCl, 1-deoxynojirimycin HCl) may also deliver benefits. In preclinical studies of AT2220 co-administered and co-formulated with Myozyme/Lumizyme, greater enzyme uptake in disease-relevant tissues led to greater glycogen reduction compared to either of these ERTs alone. Taken together these results support the further investigation of a next-generation ERT that combines AT-B200 with a pharmacological chaperone for Pompe disease. The results from that study demonstrated that co-administration of oral AT2220 just prior to infusing Myozyme/Lumizyme increased GAA enzyme activity in muscle tissue compared to that of ERT alone. Phase 2 clinical study (ClinicalTrials.gov Identifier: NCT01380743) has been initiated to investigate the effects of co-administered AT2220 on rhGAA in Pompe patients [68, 69].
ADAs decrease GAA enzyme uptake by muscle and/or inhibit its activity. Current approaches for mitigating GAA-ADA are based on treatment with methotrexate (MTX) to inhibit proliferation of lymphocytes and Rituximab (Rituxan) to deplete antibody (Ab)-producing B cells [70]. Additional pharmacological agents that suppress antibody production by long-lived plasma cells might be of use, such as a drug currently in use for plasma cell leukemia and multiple myeloma, Bortezomib (Velcade) [71].
In two recent works, the researchers showed that a very low dose combination of medicines typically used to treat cancer was successful in eliminating or preventing the immune response [72, 73]. The drugs were rituximab, methotrexate and gammaglobulins - a mix of chemotherapeutic drugs, and drugs to support the immune system. These drugs were the right mix for children who had Pompe, and who most likely were not going to benefit from the enzyme treatment because of their anti-GAA immune response. The investigators showed that these two drugs, in combination with intravenous immunoglobulins (IVIG), which modify the behavior of the immune system, were effective in reversing an established immune response to Myozyme in children whose cells were not producing any GAA [72, 73]. Immune tolerance induction study started at the end of 2008 and its completion is planned for June 2017 (ClinicalTrials.gov Identifier: NCT00701701). Study to evaluate whether B-cell depletion before ERT initiation can block GAA antibody responses started in 2011, and it is still ongoing (up to 2018) (ClinicalTrials.gov Identifier: NCT01451879).
Alternative approaches that might redirect the immune response toward antigen-specific tolerance without immunosuppressive agents are needed. Methods leading to the induction of antigen-specific regulatory T cells (Tregs), using peptides such as Tregitopes (T regulatory cell epitopes) are under consideration for the future treatment of CRIM-negative Pompe disease. Tregitopes are natural T cell epitopes derived from immunoglobulin G (IgG) that cause the expansion and activation of regulatory T cells. Teaching the immune system to tolerate GAA by co-delivering GAA with Tregitope peptides might dramatically improve the lives of CRIM-negative children, as well as it could be applied to other enzyme replacement therapies to which ADA have been induced [74]. 
In vitro studies and in vivo pharmacologic investigations have demonstrated that albuterol has a preferential effect on β2-adrenergic receptors. While it is recognized that β2-adrenergic receptors are the predominant molecules on bronchial smooth muscle, data indicate that there is a population of β2-receptors in the human heart existing in a concentration between 10% and 50% of cardiac β-adrenergic receptors. 
Effective dosages for enzyme replacement therapy in Pompe disease are much higher than for other lysosomal storage disorders, which has been attributed to low cation-independent mannose-6-phosphate receptor (CI-M6P) in skeletal muscle. The earlier studies demonstrated the benefit of increased CI-M6P-mediated uptake of recombinant human acid-α-glucosidase during ERT in mice with Pompe disease following addition of albuterol therapy [58]. The recent pilot study revealed initial safety and efficacy in an open-label study of adjunctive albuterol therapy in patients with late-onset Pompe disease who had been stable on ERT with no improvements noted over the previous several years (ClinicalTrials.gov Identifier: NCT01885936) [75]. There is also an ongoing clinical study to compare the safety and efficacy of Clenbuterol (similar to the Albuterol – muscle anabolic β2-adrenergic agonist) on motor function in individuals receiving ERT (ClinicalTrials.gov Identifier: NCT01942590). 
Aerobic exercise may be used in conjunction with enzyme replacement therapy to attenuate cardiovascular deconditioning, skeletal muscle wasting, and loss of motor function in Pompe disease. Endurance training is beneficial as an adjunctive therapy to ERT in Pompe disease, although it works by mechanisms independent of a reduction in glycogen content [76]. Particularly interesting are studies on the simultaneous use of high protein level, exercise therapy and nocturnal enteral feeding (ClinicalTrials.gov Identifier: NCT01656590), but this study has been withdrawn prior to enrollment. Another pilot study is proposed to evaluate the effect of diet and exercise therapy in Pompe disease patients receiving ERT for at least one month prior to beginning of the study, but, to date, the study is not yet open for participant recruitment (ClinicalTrials.gov Identifier: NCT02363153).

Mucopolysaccharidoses
Mucopolysaccharidoses (MPSs) are caused by mutations leading to inefficient degradation of glycosaminoglycans (GAGs) in lysosomes [77]. The accumulation products are: dermatan sulfate (DS), a component of conjunctive tissues, heparan sulfate (HS), a constituent of cellular membranes, and keratan sulfate (KS) and chondroitin sulfate (CS), present in the cartilages and in the cornea. Alterations in metabolism of these GAGs cause severe complaints in patients in form of a progressive damage of the affected tissues and organs, including the heart, respiratory system, bones, joints and central nervous system. Eleven enzymatic deficits are known to be responsible for seven different types (MPS I, II, III, IV, VI, VII and IX) and numerous clinical subtypes of the mucopolysaccharidoses,. Although each MPS type differs clinically from others, most patients generally experience a period of normal development followed by a decline in physical and/or mental function [75].
MPS can be potentially treated at many levels, from classical approaches with some sophisticated molecular treatments, such as protein treatment and advanced therapies derived from genetic medicine [78].  At present the following treatments are either available for MPS patients or tested to assess their efficiency (at various stages of research): enzyme replacement therapy, bone marrow transplantation (BMT), hematopoietic stem cell transplantation (HSCT), substrate reduction therapy, small molecular chaperones (SMC), stop codon readthrough (SCR), gene therapy (GT). However, ERT, BMT and HSCT (the latest one has been shown to be effective in MPS I, although no cure can be achieved) are the only approved treatments for MPS. Following enzyme drugs, based on recombinant human proteins, are currently used in MPS patients: Aldurazyme for MPS I, Elaprase for MPS II, and Naglazyme for MPS VI. Additionally, in February 2014, the FDA approved elosulfase alpha (Vimizim; BioMarin Pharmaceutical) for the treatment of type IVA mucopolysaccharidosis. Approval was based on a study of 176 patients in which subjects treated with elosulfase alpha showed greater improvements in a 6-minute walk test relative to those treated with placebo.
A feasible and possibly effective strategy to improve MPS treatment can be the combination of particular monotherapies. Points to be considered are: combination of drugs or combination of drug and therapeutic approach, combined approaches to converge therapeutic effects, additive and synergistic effects for two or more combined treatments, and sequential or parallel treatment. Several groups have suggested that combining disparate therapeutic approaches may result in a more complete clinical correction [18, 78, 79].
Long term therapeutic effects of enzyme replacement, followed by bone marrow transplantation, in murine mucopolysaccharidosis type VII were assessed [80]. The  researchers compared the effects of long term enzyme replacement initiated either at birth or at 6 week of age, and of enzyme administration initiated at birth followed by syngeneic bone marrow transplantation at age of 5 weeks. The results indicated that all three treatment protocols have long term therapeutic effects. However, combination of early ERT followed by BMT appeared to be as effective as enzyme replacement alone and actually leads to more complete correction in some cell types. The combination of ERT followed by BMT reduced lysosomal storage in meninges, corneal fibroblasts, and bone when compared with treatment with the enzyme alone. It was concluded that both enzyme replacement alone and early enzyme replacement followed by BMT have long term positive effects on murine MPS VII [80].
Another report presnted a case of combined treatment with laronidase (Aldurazyme), noninvasive ventilation, and continuous oxygen therapy for life-threatening pulmonary complications in a patient with MPS I syndrome, 12 years after a successful BMT [81]. MPS I (Hurler syndrome) patient with repeated BMTs, at the ages of 2 and 2.5 years, developed progressive respiratory complications 10 years later. However, when within 24 months a regular ventilation and weekly laronidase therapy stared, patient’s quality-of-life scores and respiratory obstruction improved significantly. Results of this case study suggested that laronidase may be a therapeutic strategy for patients with MPS I who have received a stem cell transplant and have severe cardiorespiratory complications [81]. 
Two strategies, BMT and ERT, were investigated and compared as a mono or combined therapy using mouse model of MPS II [82]. The aim of the work was to evaluate the effect of correcting the biochemical and pathological aberrations in the viscera and CNS. The studies revealed that the combination of BMT and ERT was additive at reducing tissue levels of GAGs in the heart, kidney and lung. The conclusion was that enzyme augmentation therapy enhances the therapeutic efficacy of bone marrow transplantation in MPS type II mice [82].
Other authors described the initial multi-institution experience and observations with combined use of enzyme replacement therapy (laronidase) and HSCT in children with Hurler syndrome (MPS I) [83]. The rationale for the combined use of ERT and HSCT in this disease resulted from the hypothesis that such a combination might reduce transplant-related complications, particularly pulmonary complications. Thirteen transplants were performed in 12 patients. The median duration of pre-HSCT ERT was 12 weeks. ERT was given for a median of 7 weeks after HSCT. After transplantation, eight patients demonstrated complete donor engraftment and four suffered graft failure. Two patients required ventilator support and three developed acute Graft-Versus-Host Disease. Eleven of the 12 patients have survived with a median follow-up of 3 months. In conclusion, the authors stated that ERT in combination with HSCT is feasible, relatively safe and well tolerated in MPS I patients. At the same time, they emphasized that more prospective, i.e. international and multicenter, collaborative study is needed to determine the effect of concomitant ERT on transplant outcomes [83].
Such multi-institution trial was performed, indeed, later [84]. It was reported that a study was conducted on 22 children with MPS I who received single or multiple pretreatment with ERT in addition to hematopoietic cell transplantation (HCT), in the time range 3 – 17.5 months. The goal of that study was to analyze the effects of ERT on the ‘alive and engrafted rate’, and on the transplantation-related morbidity. The data revealed that ERT in combination with HCT was well tolerated. However, no statistically significant relation between ERT, pre-HCT, and the short-term outcome of HCT was observed. Therefore, it was concluded that selection of patients for ERT before HCT should be performed on an individual basis, although patients in a poor clinical condition at the time of diagnosis should be considered for such treatment, making them eligible for HCT [84]. Moreover it was reported that ERT in patients with MPS IH undergoing HCT improves cognitive functioning [85]. 
In the large study mentioned above, researchers concluded that the use of ERT could not be demonstrated to affect the outcome of HSCT. However, that multi-institution trial was made on patient population heterogeneous in the choice of stem cell grafts, conditioning regimens, and the number of cell infusions [84]. This was in contrast to another study on combination of enzyme replacement and hematopoietic stem cell transplantation as therapy for MPS type I (ClinicalTrials.gov Identifier: NCT00176891, and NCT01572636). In the single-institution trial and unified conditioning regimen, patients received a similar number of enzyme infusions, and it was determined whether ERT in the peritransplant period affects outcome of HSCT in 7 children with MPS I. Laronidase was administered intravenously in 11 – 14 weekly doses before HSCT, and 8 weekly doses after HSCT. In contrast to previous work that suggested treating only patients in a poor clinical condition with the combination therapy, at this time the authors’ recommendation was to treat all severe MPS I patients with combination of ERT and HSCT to improve morbidity and mortality, and generally to further investigate potential of this mixed therapy to enhance outcomes with HSCT [86].
Subsequently, the long-term follow-up of successful treatment of MPS I with combined enzyme replacement therapy and hematopoietic progenitor stem cell transplant has been reported [87], and the use of enzyme replacement therapy (laronidase) in conjunction with hematopoietic stem cell transplantation in 18 patients with severe MPS I was described [88]. The survival and engraftment rate was 89% overall and 93% for the 15 patients who received full-intensity conditioning. It was practiced to give ERT to patients with MPS I in the interval between diagnosis and transplantation in order to improve the somatic (including cardiac) manifestations of the disease, and to prepare the child for transplant conditioning therapy [88]. Moreover, quantitative and functional immunological assays were developed, and the incidence, pattern and impact of the immune response in MPS I patients prior to receiving any treatment and following ERT and HSCT were studied. The relationship between these antibody responses and metabolic biomarkers of the disease was determined. As laronidase was increasingly used as an adjuvant treatment before HSCT to improve the pre-transplant clinical condition, further considerations regarding combined treatment of MPS I were conducted [88].
Results of a European consensus procedure, describing crucial issues related to the two different therapeutic modalities, ERT and HSCT, and their combination in MPS I in order to provide clinical guidelines, were presented [89]. Full consensus was reached on several important issues, such as: (i) HSCT is the preferred treatment for patients with severe MPS I diagnosed before age 2.5 years, (ii) if there is a suitable donor, HSCT may be considered in individual patients with an intermediate phenotype, (iii) all MPS I patients including those who have not been transplanted or whose graft has failed may benefit significantly from ERT, (iv) ERT should be started at diagnosis and may be of value in patients awaiting HSCT. It was believed that this multidisciplinary project provided consensus recommendation for decision on the appropriate MPS I treatment and was an important step towards a multinational and collaborative approach in the handling of rare disorders.
More recent paper [90] described how hematopoietic stem cell transplantation improves the high incidence of neutralizing allo-antibodies observed in MPS I syndrome after pharmacological enzyme replacement therapy. The role of HSCT as an immune tolerance induction mechanism in patients with neutralizing allo-antibodies was established in that work. The impact of these antibodies in 8 patients who received ERT before and during HSCT was determined. Additionally, 20 patients who had previously received an allogeneic stem cell transplant were tested to evaluate this treatment as an immune tolerance induction mechanism. The results showed that the high-titer immune responses in MPS I patients treated with ERT can neutralize replacement therapy in a significant proportion of patients [90]. 
In summary of the ERT and HSCT combination, a number of recent publications, referred above, have demonstrated reduced HSCT morbidity and mortality from preconditioning with ERT. Supplementary ERT before HSCT rapidly reduced upper airway obstruction, and improved cardiorespiratory capacity thereby improving patient fitness for HSCT [83, 84, 86-88]. It was demonstrated that a treatment regimen of ERT combined with HSCT in 3-year-old patient with MPS VI provided similar benefit. However, long-term follow-up studies comparing the morbidity and mortality of HSCT and ERT combined with HSCT was recommended [91].
A rationale for substrate reduction therapy in MPSs is to inhibit synthesis of GAGs which cannot be efficiently degraded due to deficiency in certain enzyme activity. Studies on a very interesting genetic model for substrate reduction therapy (gSRT) indicated improved efficacy of enzyme replacement cure in cell cultures and in MPS IIIA mice [92]. MPS IIIA mice Sgsh-/- partially deficient in heparan sulfate biosynthesis due to heterozygosity in Ext1 or in both Ext1 and Ext2 genes were employed for glycosaminoglycan storage and neurological correction assessment. Heterozygous enzyme deficiency resulted in reduction of the biosynthesis of heparan sulfate by 30 – 50%, and in disease-specific biomarker level that correlates with the degree of lysosomal storage in multiple MPS IIIA mouse tissues, including the brain. gSRT significantly reduced the effective concentration of enzyme necessary for ERT in cell culture, and showed an additive therapeutic effect in vivo, suggesting that a combined SRT and ERT therapeutic approach would prove effective for treating MPS III patients [92].
Genistein, a natural isoflavone, has been proposed as a potential compound to be used in SRT for MPS as it negatively regulates GAG synthesis due to inhibition of epidermal growth factor receptor (EGFR) kinase activity and subsequent signal transduction pathway [19, 20]. Recently, it was demonstrated that apart from this activity, genistein also enhances expression of genes coding for GAG hydrolases and stimulates lysosomal biogenesis and function through modulation of transcription factor EB (TFEB) expression and activity [93]. Therefore it was tempting to suggest that the specific kind of SRT, based on genistein and called gene expression-targeted isoflavone therapy (GET IT) [21], might be used together with ERT for MPS treatment. However, to date only preliminary experiments with such a combination treatment on MPS I cell cultures have been reported which nevertheless suggested that such an approach may be effective [94].
Suppression of premature termination of protein synthesis on ribosomes (called stop-codon readthrough) provides a potential way for treatment of diseases caused by a point non-sense mutation which leads to appearance of a new stop codon within normally coding sequence. The capability of gentamicin to suppress the stop-codon in human MPS I fibroblasts carrying different nonsense mutations has been reported [95]. With one exception, gentamicin treatment increased the alpha-L-iduronidase activity in MPS I fibroblasts that were verified. Therefore, enhanced stop-codon readthrough may be potential treatment strategy or supplemental therapy for a large number of MPS I patients, potentially in combination with ERT [95].
Another potential possibility is to combine ERT with small molecular chaperones. Chaperone-advanced replacement therapy, with the use of human recombinant IDUA (rhIDUA) enzyme, co-formulated with a novel pharmacological chaperone, has been announced as a next-generation therapy for MPS I (Amicus Therapeutics, http://www.amicusrx.com/preclinical.aspx (​http:​/​​/​www.amicusrx.com​/​preclinical.aspx​)). However, no specific results were published to date on effectiveness of such a combined method.
A report published a few years ago described enhancement of the effects of enzyme replacement therapy via anti-TNF-alpha treatment in rat model of MPS type VI [96]. MPS VI rats were treated for 8 months with Naglazyme, or by a combined protocol using Naglazyme and the rat-specific anti-TNF-alpha drug, CNTO1081. While ERT-mediated improvement in motor activity and mobility was significantly enhanced by combination treatment, tracheal malformations in the MPS VI animals were only improved by a combined ERT and anti-TNF-alpha approach. Both protocols did not demonstrate any significant positive effects on bone microarchitecture and bone growth. The results demonstrated that combining ERT with anti-TNF-alpha therapy improved the treatment outcome, provided several benefits over ERT alone and led to significant clinical benefit. Therefore it was concluded that further evaluation of this combination approach in other MPS animal models and patients is reasonable [96]. Two years later, the same group has published their studies on the use pentosan polysulfate (PPS), an FDA-approved oral medication (ElmironH) with anti-inflammatory properties in the rat model of MPS VI (97). PPS effects on the skull, dentition and motility were more significant than those observed previously with anti-TNF-alpha antibody therapy. Therefore, it was suggested that it will be important to evaluate the combination of ERT and PPS, and to determine the additive benefit of this drug. The authors proposed that PPS could be a safe and cost-effective treatment that might be utilized in combination with ERT, HSCT or other therapies for all MPS patients to improve the clinical results. An open label clinical trial, devoted to investigate the safety of weekly pentosan polysulfate injections in adult patients with mucopolysaccharidosis type I receiving enzyme replacement therapy, has been registered (clinicaltrialsregister.eu EudraCT number 2014-000350-11). Two clinical trials of combined therapies of ERT and antigen-specific immunosppressive agents are also registered (ClinicalTrials.gov Identifier: NCT00741338, and NCT01602601).
Over two decades ago, correction of murine mucopolysaccharidosis type VII by bone marrow transplantation and gene transfer therapy was reported (98). More recently, results of combining intracranial gene therapy and bone marrow transplantation, compared with either approach alone in the mouse model of MPS IIIB, were published [99]. It was hypothesized that combining CNS-directed GT with BMT in the neonatal period would result in correction of the disease due to increased enzyme activity levels and reduced inflammation in the brain. In fact, adeno-associated virus (AAV)-BMT treatment resulted in improvements in hearing, time to activity onset, motor function, and reduced CNS lysosomal storage, but had no effect on lifespan. Combination therapy compared to either therapy alone resulted in synergistic effects on hearing and CNS lysosomal inclusions but antagonistic effects on motor function and lifespan. AAV alone was more efficacious than BMT or combined AAV and BMT treatment for lifespan. BMT was the least efficacious treatment by all measures. CNS-directed AAV treatment alone appeared to be the preferred treatment, combining the most efficacy with the least toxicity of the approaches assessed [99].
In addition to actual combinations of different therapeutic methods, specific modifications of treatments of MPS were also proposed. One study verified combined avenues of sulfamidase delivery for treatment of MPS IIIA [100]. A naturally-occurring MPS IIIA mouse model was employed to determine the effectiveness of combining intravenous protein replacement (IV-PR) from birth to 6 weeks of age with intra-cerebrospinal fluid (CSF) sulfamidase delivery (from 6 weeks of age) on behavior, the level of storage heparan sulfate and other neuropathology. Animals treated in this way exhibited similar clinical improvement and reduction in HS accumulation to those only receiving intra-CSF sulfamidase protein. In both groups reductions in micro- and astrogliosis and delayed development of ubiquitin-positive lesions were observed. A third group of intravenous-only treated mice did not exhibit clinical or neuropathological enhancements. Intra-CSF injection of the enzyme dose-dependently improved neurological pathology in MPS IIIA, even when treatment begun in mice with established disease [100]. 
Another option is the use of the minicircle DNA-based technology coupled with immune modulation (IM) for the nonviral gene therapy (NV GT) of mucopolysaccharidosis type I [101]. This nonviral gene delivery system, mediated by hydrodynamic DNA injection for expression of recombinant gene being under the control of a liver specific promoter, in conjunction with microRNA target sequences, permitted long-term expression of modified IDUA gene (coding for immunogenic α-L-iduronidase) in mice with MPS I. Immune modulatory strategy involving co-stimulatory blockade was required, and permitted for IDUA expression in MPS I mice that resulted in the biochemical correction of pathology in all of the analyzed tissues. Researchers identified the clinically applicable approach of combined co-stimulatory blockade of immune cell surface proteins B7:CD28 and CD40:CD40L as the optimal immune modulation that resulted in prolonged IDUA expression. However, critical to this is the safety of this vector system affords due to its maintenance as an extrachromosomal episome. 
Finally, murine MPS IIIB correction by combined neonatal intracranial adeno-associated virus (IC-AAV) and intravenous lentiviral (IV-LENTI) gene therapy has been reported [102]. In this attempt, MPS IIIB mice were treated at 2 - 4 days of age with IC-AAV, IV-LENTI or the combination of both. It was demonstrated that neonatal treatment with either an intravenous injection of a lentiviral vector, intracranial injection of an AAV vector or the combination of both can significantly improve surrogates for quality of life (motor function, hearing, and circadian rhythm) and increase life span. In fact, the most complete biochemical and histological improvements of any treatment group, as well as the greatest increase in life span, was observed for MPS IIIB mice cured with the combined strategy [102]. 

Niemann-Pick disease type C
Niemann-Pick disease type C1 (NPC1) is another neurodegenerative disease which results in storage of glycosphingolipids (GSLs). In addition, cholesterol is accumulated in NPC1 lysosomes. The neuropathological features are characterized by progressive loss of Purkinje cells in the cerebellum and neurons [103]. 
Possible treatments include blocking the intestinal absorption of cholesterol with Ezetimibe [104], or inhibition of protein hyperphosphorylation [105]. A promising approach for the treatment of NPC1 is SRT with NB-DNJ (miglustat). Miglustat not only delayed onset of clinical signs, and increased lifespan of Npc1-/- mice [106], but also normalized lipid trafficking [107], and improved clinical signs in human patients [108, 109]. Another therapeutic approach is by-product replacement therapy (BRT) based on replacing missing or deficient products needed for normal cellular functioning. An agent tested in this strategy was allopregnalone, a neurosteroid shown to be deficient in the CNS of Npc1-/- mice. Mice treated with allopregnalone exhibited delayed clinical onset, extended lifespan, and reduced ganglioside (GM) levels [110]. Combining those two therapies (BRT+ SRT) had a synergistic effect on delay of disease progression in Npc1-/- mice, more efficiently than either monotherapy. However, action of allopregnalone as an effective agent has been questions subsequently [110]. Combining those two therapies (BRT+ SRT) had a synergistic effect on delay of disease progression in Npc1-/- mice, more efficiently than either monotherapy. However, action of allopregnalone as an effective agent has been questions subsequently [111]. Efficacy of the combined treatment has also been evaluated by its impact on corneal alterations as a consequence of GM2 accumulation [18]. Corneas of wild type and Npc1-/- mice responded differently to Cyclo/ALLO/Miglustat treatment and varied between individual mice, revealing an absolute remission of deposits in some animals and still pronounced accumulations in the others. Overall, combined treatment significantly reduced number of affected cells and intensity of inclusions in mouse cornea. This finding was confirmed by significant reduction of GM2 ganglioside and cholesterol concentration. On the other hand, there was an increase in numbers of dendritic cells that might suggest mild allergic inflammation of corneal surface of unknown etiology [112]. That type of treatment has been also studied by its impact on behavior of  Npc1-/- mice. In this case combination therapy had positive impact on motor dysfunction, however it did not bring any benefit for cognitive functions [113]. 
Another therapeutic strategy which has been demonstrated recently is to combine SRT (miglustat) with curcumin and ibuprofen, belonging to nonsteroidal anti-inflammatory drugs (NSAIDs). This approach have been tasted on Niemann-Pick type C1 mice and was based on the hypothesis that miglustat will target sphingolipid synthesis and storage, curcumin should compensate lysosomal calcium defect, and ibuprofen will reduce CNS inflammation. Such triple combination therapy had a greater neuroprotective benefit than mono- or dual-therapy [114].
One of possible treatments for NPC is reduction of the oxidative stress. Combination treatment of two antioxidants (tamoxifen and vitamine E) had been tested on NPC1 mice. Simultaneous use of these both agents did not delay weight loss greater than tamoxifen alone, but it had a positive impact in behavioral tests. Interestingly, some sex differences in response to that kind of treatment had been observed [115].
Beside those merged therapies, based on different mechanism of action, other approach was to combine different administration regiments. This concerned the ex vivo gene therapy with a retroviral vector using bone marrow-derived cells [116]. Via intravenous injection, Niemann-Pick mice received transduced bone marrow cells overexpressing human acid sphingomyelinase (ASM), and after engraftment, those mice received intracerebral injections of mesenchymal stem cells obtained from originally transduced bone marrow. Most of the treated NPC mice had increased levels of ASM activity, improved histology and reduction in sphingomyelin. Unfortunately, this positive effect was not permanent and dramatically reduced during the time. When the immunological response to anti-human ASM began, the cerebellar function started to decline [117].
Effects of combination of brain and systemic injections of recombinant adeno-associated viral vectors encoding human ASM had been tested in a mouse model of NPC. Mice treated by combination therapy exhibited high levels of hASM in the visceral organs and brain. Furthermore, animals in the group which received combination therapy did not generate antibodies to hASM, what had been reported as a problem with long term maintained efficacy [118].
AAV1-hASM had also been tested as a potential treatment for Niemann-Pick type A disease (NPA). To establish the level of hASM that will have therapeutically effect, ASM knockout mice (ASMKO) received intracranial injections of different doses of AAV1-hASM vector. When the dose was established, non-human primates (NHP) received 12 tracts of AAV1-hASM which resulted in efficacious levels of enzyme in a broad region in the brain. This study demonstrated that a combination of cortical, subcortical and cerebellar injections could provide therapeutic levels of hASM to different regions of the NPA patients’ brains [116].

Sandhoff disease
Significant group among LSDs are glycosphingolipidoses, pediatric neurodegenerative diseases that are caused by inborn errors in glycosphingolipid catabolism. The substrate for the defective enzyme accumulates in the lysosome which leads to pathology. GSLs derived from glucoceramide (GlcCer) are found throughout the body and galactosylceramide (GalCer) and its sulfated derivative sulfide play roles within the central nervous system, particularly contributing to the formation and stability of myelin (119). Sandhoff disease (SD) is ceased by mutation in the HEXB gene which encodes β-subunit of β-hexosaminidase, leading to GM2 ganglioside accumulation [103].
Most of the effort to treat these diseases has focused on treatment delivery to the CNS. This potential therapeutic approaches can be divided into two major groups. The first group contains methods of increasing the enzyme levels such as intravenous enzyme replacement, bone marrow transplantation, stem cell therapy, and gene therapy. The second group is based on methods to balance the rate of GSL biosynthesis with the impaired rate of catabolism such as substrate reduction therapy with two classes of inhibitors that either inhibit the ceramide-specific glucosyltransferase, an enzyme that inhibits the GSL biosynthetic pathway by catalyzing the transfer of glucose from UDP-Glc to ceramide, such as D-threo-l-phenyl-2-decanoylamino-3-morpholino-1-propan (PDMP), its derivative 1-phenyl-2-palmitoylamino-3-morpholino-1-propanol (PPMP) [120], or immino sugars N-butyldeoxynojirimycin  (NB-DNJ) or N-butyldeoxygalactonojirimycin (NB-DGJ) which down regulate ganglioside biosynthesis due to its competitive inhibition of GlcCer synthase [121]. It was reported that symptomatic mouse model of Sandhoff disease treated with NB-DNJ have delayed symptoms’ onset, reduced storage in brain and visceral organs as well as increased lifespan for about 40% [122]. Similar effects were achieved due to BMT. Treated mice extend the lifespan from ~4.5 mo. up to 8 mo. and had corrected biochemical deficiencies in visceral organs [123]. 
Because the enzyme supplementation via BMT and SRT might act synergistically, the efficacy of combining these two therapeutic strategies was evaluated. Mice treated with both therapies survived significantly longer than those which received only BMT or NB-DNJ [124]. However, although there was a significant correlation between survival and β-hexoaminidase levels in the brain and spinal cord, it was not in visceral organs. In fact, mice receiving combination therapy performed better in behavioral tests, and the rate of decline was significantly slower than in all other groups. On the other hand, brain GM2 level was approximately 30% higher in mice receiving combination therapy than in any of the monotherapy groups [124].
Substrate reduction therapy with NB-DGJ has also been tasted in combination with neuronal stem cells (NSCs) transplantation. NB-DGJ is more selective GSL biosynthesis inhibitor than NB-DNJ, with less severe side effects [107]. Combination of intracranial transplantation of NSCs with intra peritoneal injection of NB-DGJ did not have any additive or synergistic effect relative to SRT monotherapy [108]. 
Another therapeutic option that has been tested on the mouse model of Sandhoff disease was combination of gene transfer and SRT. Sandhoff mice were treated by stereotactic inoculation of recombinant adenoassocieted viral vector (rAAV) encoding β-hexosaminidase at a single site in the striatum, combined with SRT with miglustat. This combination strategy was neither synergistic nor additive in this animal model as no extended lifespan nor reduced GM2 accumulation in brain could be observed.
The major problems in Sandhoff disease in an inflammatory response as a consequence of GM2 storage in the brain. One of the tested approaches was to treat mouse model of Sandhoff disease with the nonsteroidal anti-inflammatory drugs such as indomethacin, aspirin and ibuprofen, as well as antioxidative agents, vitamins C and E, combined with SRT. All tested therapies were beneficial for neurological function. Life expectancy was improved by NSAID additively by combining with vitamin E. Moreover, merging NSAIDs with SRT (NB-DNJ) showed synergy ranging from 6% (indomethacin) to 11% (aspirin) [125].
One might consider a treatment based on a restricted diet, for example the restricted caloric katogenic diet (KD-R) which is a high fat, low carbohydrate diet that has been shown to improve motor function and to increase longevity in Sandhoff disease mice [126]. Combination of KD-R with SRT enhanced therapeutic benefits of monotherapies. Moreover, NB-DNJ level detected in brain tissue in mice receiving combined therapies was significantly greater, which suggests that combining these two therapies facilitates NB-DNJ penetration into the brain. This fact may allow to lower dosing of NB-DNJ in order to achieve the same efficacy as high dose monotherapy [127]. Furthermore, this therapeutic option is being tested as an open label clinical trial, Synergistic Enteral Regimen for Treatment of the Gangliosidoses (Syner-G) (ClinicalTrials.govIdentifier: NCT02030015). Infantile and juvenile patients with not only Sandhoff disease, but also Tay-Sachs, receive miglustat and ketonic diet. No results of this study are available to date. Nevertheless, one case of miglustat and ketonic diet combined treatment was described in 6-year-old male with Sandhoff disease [128]. Initiation of treatment was followed by improvement of the patient's seizure control and cardiac function but further clinical investigation is still required to better determine the benefit of management in late-onset forms of Sandhoff disease. There is also ongoing phase 1 clinical trial to estimate the efficacy of unrelated umbilical cord blood transplantation (UCBT) combined with  intrathecal administration of DUOC-01 as an adjunctive therapy in patients with inborn errors of metabolism who have evidence of early demyelinating disease in the central nervous system (CNS) (ClinicalTrials.gov Identifier: NCT02254863). It recruits patients with Sandhoff disease, Tay-Sachs disease, Krabbe disease, MPS II, and metachromatic leukodystrophy (MLD).
Another clinical trial (phase 2) tests the effectiveness and safety of a novel conditioning regimen in attaining donor blood stem cell engraftment in persons with certain inherited metabolic disorders. Allogenic hematopoietic cell transplantation (HCT) for Sandhoff disease, as well as many other LSDs, is accompanied by conditioning with certain therapeutic drugs like busulfan, methylprednisolone and mycophenolate mofetil (MMF) (ClinicalTrials.gov Identifier: NCT02171104). It is a follow-up of completed studies (ClinicalTrials.gov Identifier: NCT01626092 and NCT00383448).

Tay-Sachs disease 
Tay-Sachs disease is caused by mutations in the HEXA gene which encodes the α-subunit of β-hexosaminidase. Such mutations lead to GM2 ganglioside accumulation [103]. The therapeutic options are limited, and basically similar to that for Sandhoff disease. Little information can be found about combination therapy for this disorder. One of the potential option is co-application of a pharmacological chaperone and a proteostasis regulator (PR). Cellular protein homeostasis (proteostasis) involves controlling the conformation, concentration, binding interactions and location of individual proteins making up the proteome. PRs can partially restore mutant HexA folding, trafficking and function in Tay-Sachs patient-derived cell lines [38]. ADNJ functions as a protein chaperon in fibroblast derived from Tay-Sachs patient [129]. Combined proteostasis regulator MG132 with chaperon ADNJ demonstrated synergy and increased enzyme activity greater than any of this compound used as a monotherapy [38].

Krabbe disease
Globoid cell leukodystrophy (GLD), or Krabbe disease, is an autosomal recessive disease caused by a defect in β-galactosylceramidase (GALC). Its pathology involves galactosylosphingosine (psychosine) accumulation with progressive demyelination of CNS and PNS [130]. Neurologic manifestations occur with astrocytosis, accumulation of macrophages and severe inflammatory response [131].
Currently, the only treatment for this disease in human patients is cell therapy based on transplantation of hematopoietic stem cells derived from bone marrow or umbilical cord blood [132, 133]. This therapeutic approach provides a source of missing enzyme, bringing beneficial effects especially to unaffected newborns [133]. Transplantation in patients after the onset of symptoms results in normal leukocyte GALC levels and partial inhibition of further progression of the disease [132]. Several clinical trials are recruiting patients or currently ongoing, aiming to reduce pre-transplantational immunosuppressive conditioning and enhance engraftment process by enriching stem cells (ClinicalTrails.gov). 
At this time all other investigated treatments were tested on animal models, in particular on naturally occurring murine model of Krabbe disease, the twitcher mice [134]. Cells transplantation-based therapy was evaluated using this mouse model. Murine neural stem cell or genetically modified neural progenitor cells were injected into the brains of newborn twitcher mice. Nevertheless, the course of the disease has not been changed as only partial clinical improvement was observed  [135, 136].
As Krabbe disease presents neurological symptoms, little has been shown about enzyme replacement therapy. Some research has been conducted, based on intraperitoneal (IP) and intracerebroventricular (ICV) injection of recombinant murine β-galactosylceramidase. Modest increase in life span has been obtained and no alteration of natural history of the disease has been observed [137, 138]. Nevertheless ERT for Krabbe disease is being developed and in 2011 ACE BioSciences has gained the Orphan Drug Designation for recombinant human galactocerebrosidase for the treatment of globoid cell leukodystrophy (EU/3/11/911) (http://ec.europa.eu/health/documents/community-register/html/o911.htm). Another approach is to provide missing enzyme by gene therapy, based on viral vector transfering a functional GALC gene delivered into the brain of twitcher mouse. Recently, a study on lentiviral- mediated treatment has shown a beneficial effect on extending life span and stable restoration of enzymatic activity [139]. Substrate reduction therapy has been suggested as a possible treatment since L-cycloserine has been shown to delay GLD progression and increase life span of twitcher mice [140]. Some other therapies have been tested, like small molecule chemical chaperone or non-steroidal anti-inflamatory drugs, both with limited or not yet well estimated improvement in measured effects [141-144].
Most of combined approaches for GLD use HSCT as it became a first choice treatment for metabolic leukodystrophies [131], thus a combination of enzyme replacement therapy and bone marrow transplantation has been proposed. Newborn twitcher mice (2-3 day of life) received intracerebroventricular and intrathecal injection of recombinant enzyme and BMT the day after. The study has shown beneficial effects of this combination on increasing the life span and correcting the behavioral phenotypes. Reduced psychosine level and significant reduction of neuroinflamation markers (CD68 and GFAP) were achieved as well. These results indicate that ERT and BMT can produce synergistic effects when combined [145]. Nevertheless, the procedure must be performed in presymptomatic stage of the disease, as progression of GLD is extremely fast and patients are often diagnosed after onset of clinical symptoms. To omit the blood-brain barrier (BBB), intracerebroventricular and intrathecal injection is necessary, which is an invasive and drastic procedure, especially for young patients.
Another combinatory treatment tested on twitcher mouse model is bone marrow transplantation and gene therapy. Newborn mice received CNS-directed or intravenous injection of viral (adeno-associated viral or lentiviral) vectors expressing murine GALC and BMT [146-148]. Significant increase in life span and improvement in motor functions were observed in all these studies after treatment by both therapies simultaneously. CNS-directed adeno-associated virus 2/5 (adeno-associated virus 2 pseudotyped with AAV 5 capsid) GT combined with BMT show notable reduction in galactosylosphingosine [146, 147] and decrease in inflammatory response [146]. GALC activity long term reconstitution was achieved in lentiviral gene therapy with markedly preserved myelin level [148]. Although serious valuable effects of combination of these treatments in mouse model of GLD were observed, all animals died with symptoms of progressive neurological degeneration [146, 148]. 
Although BMT and GT provide modest benefits in both presymptomatic children and the murine model (twitcher), a combination of hematopoietic stem-cell transplantation and CNS-directed gene therapy with substrate reduction therapy (with L-cycloserine, an inhibitor of 3-ketodyhrosphingosine synthase) has been reported recently [149]. This simultaneously treating multiple pathogenic targets resulted in an unprecedented increase in life span. Triple-treated twicher mice had a median lifespan of almost 300 days, with range of 160 – 454 days, while for those treated with L-cycloserine alone or plus CNS-directed GT it was 57 and 70 days, respectively. Improved motor function, persistent GALC expression, nearly normal psychosine levels, and decreased neuroinflammation estimated along treatment stands for the opposite to peripheral neuropathy changes that are not prevented by the triple therapy. 
SRT has been also suggested to give more pronounced effect with residual enzyme activity present, that is why bone marrow transplantation and substrate reduction therapy is an interesting combination. Twitcher mice were treated with L-cycloserine, (by subcutaneous injection), and BMT [150]. The study has shown a beneficial effect on body weight and life span – the longest ever achieved for twitcher mice (longest living mouse died in 226 days, mean from combination treated 112 days, untreated 37 days). Other improvement effects have been observed, like reduced astrocytosis and demyelination. In summary, substrate reduction therapy could be used as a supplementary therapy together with BMT to increase the life expectancy beyond that of each treatment alone [150].
Psychosine is known to induce oxidative stress in cultured cells, which can be ameliorated through addition of antioxidant N-acetylcysteine (NAC). However, when twitcher mice received bone marrow transplantation and supplementation with NAC (in drinking water and by IP injection), no therapeutic effect was measured, neither increase nor decrease in life span or behavioral improvement was noted, and no positive alterations in myelin quantity and organization could be observed [151].
A dietary approach has been tested, to estimate the counteracting effect of isoflavones and antioxidants on the toxicity derived by psychosine accumulation. Twicher mice received diet without galactose, enriched with soy isoflavones and antioxidants. Combination treated mice revealed increased life span and delayed onset of tremors. In that study, cytotoxicity of antioxidants was measured in mouse oligodendrocyte progenitor cells [152]. Although it was not intended in that study, recent results indicated that isoflavones can also potentially act as agents causing reduction of galactosylosphingosine synthesis efficiency [93], thus, the experiments described above can be treated as a combination of SRT and antioxidants. Further studies might indicate whether such a combination of therapeutic approaches can be effective in reducing neurological symptoms, particularly at higher doses of isoflavones. This may be important in the light of demonstration that a correction of behavior after administration of high doses (160 mg/kg/day) of genistein was reported previously in the mouse model of MPS IIIB, which was accompanied by extensive studies on cultures of human fibroblasts (for a review, see [21]).

Metachromatic leukodystrophy
Mutations in the ARSA gene, resulting in deficient arylsulfatase A (ARSA) activity, lead to accumulation of sulfogalactosylceramide, and subsequent progressive demyelination in the central and peripheral nervous system. This causes developmental stagnation or regression and various neurological symptoms (progressive coordination and speech problems, seizures, and behavioral disturbances), known as metachromatic leukodystrophy or MLD [153]. Three forms of this disease are distinguished with respect to the age of first symptoms onset: a late-infantile (onset before 3 years of age), a juvenile (onset before 16 years) and an adult one. So far there is no specific treatment for MLD.
Hematopoietic stem cell transplantation has been advocated as a therapy for MLD since 1990 [154], and is now being used worldwide. However, it failed to show efficacy in the late infantile clinical form of MLD [155]. On the contrary it halted the progression of adult and late-onset juvenile MLD [156]. Twenty seven patients were described who underwent umbilical cord blood transplantation (UCBT), stating that this procedure benefits children with presymptomatic late-infantile MLD or minimally symptomatic juvenile MLD [157]. Generally, in stem cell transplantation early intervention correlates with optimal outcomes [158]. Still some efforts are taken to rise the efficacy of this method, likewise intravenous busulfan administration in a pretransplant regimen [159].
Applicability of ERT in MLD is challenged by the blood-brain barrier. Intravenous ERT with Metazyme (ARSA derived from CHO cells, also known as HGT-1111, product of Shire) proved not to be efficacious and further development of this product was ceased in February of 2010. At the moment, phase 1/2 clinical study of HGT-1110 (a formulation of ARSA derived from human cells) administered intrathecally in children with MLD (ClinicalTrials.gov Identifier: NCT01510028) is ongoing, and Shire is recruiting patients (ClinicalTrials.gov Identifier: NCT 01887938) to collect long-term safety data in patients with MLD who are receiving HGT-1110 and have participated in the previous study. Attempts to promote brain delivery of the enzyme are made by generation of BBB-penetrating fusion proteins of ARSA and different peptide vectors [160, 161]. These are still in pre-clinical development.
Small molecule-based therapy can potentially overcome limitations of the current therapies for MLD and may also tackle, at multiple levels, different pathogenic and molecular mechanisms involved in MLD [158]. Different mechanisms of action of small molecules can be considered. For example, warfarin - an antagonist of vitamin K, was hypothesized to mitigate the MLD phenotype by reducing the formation of sulfatides, so it would be the substance for SRT. However, the study in four advanced cases of MLD did not demonstrate any beneficial effects of this compound [162]. Small molecules could also act as PCs or proteostasis regulators, improving protein folding capacity of cells, resulting in the enhancement of folded mutant proteins. Recently, a quantitative cell-based high throughput screening (HTS) assay was developed to identify small molecules for mutant ARSA [163], opening a novel opportunity to identify numerous small molecules, as several potential therapeutic targets are accessible in this disease-cellular environment. Recognized specific small molecules able to rescue misfolded enzyme could work in conjunction with ERT by interacting with and, consequently, stabilizing the administered recombinant ARSA, extending its half-life in either extra or intracellular compartments [158].
Effects of gene transfer to CNS, like significant inhibition of the accumulation of sulfatide together with improvement in motor skills and behavior demonstrates that MLD mice model can be effectively treated through neonatal systemic injection of ssAAV9/ASA [164]. Intracerebral gene therapy of ARSA via administration into the white matter was also found in to be safe for nonhuman primates and yields the widest distribution of ARSA, making it the most suitable route of vector delivery [165, 166]. Newly arisisng type of MLD treatment is also the use of patient-derived induced pluripotent stem cells (iPSCs) to generate long-term self-renewing neuroepithelial stem cells and astroglial progenitors for cell-based ARSA replacement. Following transplantation of ARSA-overexpressing precursors into ARSA-deficient mice, significant reduction of sulfatide storage was observed [167].
At the moment, there are two ongoing clinical trials – phase 1/2 – on gene therapy for MLD. One with adeno-associated virus serotype rh.10 (AAVrh.10) vector used to transfer the ARSA cDNA coding for ARSA enzyme into the brain of children (ClinicalTrials.gov Identifier: NCT01801709) [166], and the other with autologous hematopoietic stem/progenitor cells collected from the bone marrow and transduced ex vivo with a lentiviral vector encoding the human ARSA cDNA under the control of the human phosphoglyceratekinase (PGK) promoter, at the dose: ≥ 2 x 106 transduced CD34+ cells/kg (maximum 20 x 106) at bedside for infusion (ClinicalTrials.gov Identifier: NCT01560182). The latter is, in fact, a combination of gene and cell transplantation therapy called cell-mediated gene therapy. This approach with the use of different cell lines was intensively studied in Arsa-/- mice, as reviewed elsewhere [131]. The advantage of gene and cell mediated gene therapy is the reduction in risk of graft-versus host disease, however, the risk of mutagenesis of cancer-related genes or oncogenes remains unknown. 

Neuronal ceroid lipofuscinosis
Neuronal ceroid lipofuscinosis (NCL) is a group of severe neurodegenerative lysosomal storage diseases characterized by intracellular accumulation of ceroid lipofuscin in neurons. NCLs share similar symptoms and signs such as retinopathy, epilepsy, and dementia. Previously, the NCLs were classified into different forms on the basis of age of onset as well as clinical and electron microscopic findings. The presently used nomenclature is based on the genetic findings and divides the NCLs into ten forms, CLN1-CLN10 (ceroid lipofuscinosis, neuronal) [168, 169], whereas CLN3 arises from dysfunction of the CLN3 protein, with dominant role in cellular trafficking, and with special consideration to endocytic and exocytic neuronal transport process. Adult neuronal ceroid lipofuscinosis (ANCL) is caused by mutation in CLN4 gene, while CLN5 – CLN8 stands for LINCL variant and CLN9 for Batten disease variant. The most severe of the NCLs in humans is CLN10 (congenital NCL), where the missing protease is cathepsin D, normally occurring in high levels in the central nervous system.
Despite intensive studies, there is no effective and approved therapy for NCL. Studies  with intravenous (IV) high-dose enzyme replacement therapy with recombinant PPT protein in CLN1 mice resulted in reduced visceral lysosomal storage and modestly prolonged survival, but only in mice treated from birth [58]. Large-volume intrathecal (IT) administration strategy to deliver therapeutic amounts of TPP1 to the central nervous system tested in CLN2 mouse [170, 171] and dog [172-175] models, resulted in decreased amount of autofluorescent storage but the increase in life-span, significant reversal of pathology and improvement in neurological phenotype were observed in the mouse but not dog model. BioMarin provided preliminary data from ongoing phase 1/2 open-label dose-escalation study of intracerebroventricular administration of cerliponase alfa (BMN 190) – a recombinant form of human TPP1, for treatment of CLN2 disorders (ClinicalTrials.gov Identifier: NCT01907087). Interim data indicated that the treatment appeared to show stabilization of  motor and language function. Mycophenolate mofetil (CellCept), an immunosuppressive agent in allogenic transplants in pediatric patients (also LSDs), approved by the Food and Drug Administration (FDA) for pediatric use is also tested in phase 2 clinical study in ambulatory children with CLN3 to evaluate impact on clinically relevant features of the disease, including motor features, seizures, behavior, cognitive and functional measures (ClinicalTrials.gov Identifier: NCT01399047).
	Gene therapy for global cerebral diseases is actually most studied method and presents a number of anatomical and technical challenges regarding therapeutic delivery. Studies on viral related vectors were described for at least four NCL’s with few animal models, including non-human primates [176-179]. Clinical studies are ongoing to evaluate the concept that persistent expression of the CLN2 cDNA in the CNS will result in the production of sufficient amounts of TPP-I after administration of AAV2CUhCLN2 (ClinicalTrials.gov Identifier: NCT00151216) and AAVrh.10CUhCLN2 vestors (phase 1/2, ClinicalTrials.gov Identifier: NCT01161576, NCT01414985).
Human CNS stem cells (HuCNS-SC) direct neurosurgical transplantation of allogeneic HuCNS-SCs into the cerebral hemispheres and lateral ventricles represented the first-in-human clinical trial involving transplantation of a purified population of human neural stem cells for a neurodegenerative disorder. Observations regarding efficacy of the intervention were limited and restricted by the enrollment criteria requiring that patients be in advanced stages of disease [180].
Decline of visual perception is an early symptom in most forms of human NCL, indicating that the retina is highly vulnerable to NCL pathologies [181]. Studies on effects of  supplementation with curcumin and DHA alone demonstrated changes in the microglial phenotype and partially improved retinal function in CLN6 mice [182]. A short-term human clinical trial of mycophenolate mofetil as immunosuppressive treatment for retinal degeneration in CLN3 was also conducted, however longer term effects, and whether immunosuppression modulates vision loss, have not been studied [183].
Because of limited number of therapeutic approaches in NCL connected with enrolled organs and symptoms, new potential drugs and administration procedures are studied. For CLN1 mimeting enzyme drugs – phosphocysteamine and N-acetylcysteine known lysosomotropic drugs have shown only modest effect on PPT substrate accumulation in INCL lymphoblasts [184, 185]. Cysteamine bitartrate (Cystagon) has been shown to reduce the storage material in PPT1 deficient cells (CLN1) but in case of open label, nonrandomized trial in individuals with juvenile-onset NCL did not result in overall attenuation of disease progression [186]. However, combination of oral cysteamine bitartrate and N-acetylcysteine in CLN1 patients failed to show any improvement of  treatment results [187].
CLN2 studies revealed a novel use of FDA-approved lipid-lowering drugs gemfibrozil and fenofibrate alone both up-regulating mRNA, protein, and enzymatic activity of TPP1 in primary mouse neurons and astrocytes as well as human astrocytes and neuronal cells [188]. It was suggested that flupirtine, a centrally acting non-opioid analgesic, has the potential to slow disease progression in CLN2 (LINCL) [189].  It was shown that flupirtine also protects CLN3-deficient human lymphoblasts and prevents CLN2- and CLN3-deficient human-derived neurons from apoptosis [190]. Parent-reported benefits of flupirtine in CLN3 patients were not supported by quantitative data [191]. Another studied purpose in CLN3 was to use resveratrol, an antioxidant that may have a curative effect in many neurodegenerative diseases. Levels of apoptosis markers, estimated in lymphoblast cells, decreased during resveratrol treatment [192].
Although the above mentioned therapeutic approaches had some positive effects, one may assume that only combination of different procedures may be of high efficacy. Purpose to use insulin-like growth factor 1 (IGF-1) and IGF-1 complexed with mesoporous silicon nanoparticles (NPs) was tested in CLN1 (INCL) mouse model. IGF-1 is important in embryonic development, and it is considered as a potential therapeutic agent for several disorders of peripheral and central nervous system and also the main trophic factor in the CNS during early brain development. In circulation, IGF-1 is mainly bound to its carrier protein, IGF binding protein-3 (IGFBP-3). As a therapeutic agent, IGF-1 has shown to be more active as free rather than in a complexed form, however, this may cause side effects during the prolonged treatment. Biodistribution, pharmacokinetics, and bioavailability of radiolabeled free IGF-1, IGF-1/IGFBP-3, and IGF-1/NP complexes in a Cln1-/- knockout mouse model was analyzed. IGF-1/NP was mainly accumulated in liver and spleen in all studied time points, whereas minor and more constant amounts were measured in other organs compared to free IGF-1 or IGF-1/IGFBP-3. The sustained release to blood and low tissue concentrations of IFG-1 delivered with nanoparticles might decrease the side effects like hypoglycemia without losing the therapeutic effect. Low blood and tissue concentrations, together with constant and sustained release, might be beneficial for the continuous IGF-1 therapy for INCL [193]. 
Combination of bone marrow transplantation with central nervous system-directed adeno-associated virus mediated gene therapy was tested in the CLN1 mouse. At birth, Ppt1-/- and wild-type mice were given either intracranial injections of AAV2/5-PPT1 or bone marrow transplantation, separately as well as in combination. AAV2/5-mediated gene therapy alone resulted in significant histological correction, improved motor function, and increased life span. Interestingly, the addition of BMT further increased the survival of treated mice and led to sustained improvements in motor function [194]. CNS-directed, AAV-mediated gene therapy was also combined with MW01-2-151SRM (MW151), a blood-brain barrier penetrant, anti-neuroinflammatory small molecule that attenuates glial cytokine upregulation and decrease seizure susceptibility, in models of neuroinflammation such as traumatic brain injury, Alzheimer's disease, and kainic acid toxicity [195-197]. Combination of AAV-mediated gene therapy with MW151 resulted in increased life spans, improved motor performance, and eradication of seizures in treated CLN1 mice. Decreased brain atrophy, astrocytosis, and microglial activation, as well as intermediary effects on cytokine upregulation was also observed [198]. 
Co-administration of recombinant TPP1 with a 36-residue peptide that contains polylysine and a low-density lipoprotein receptor binding sequence from apolipoprotein E resulted in supraphysiological levels of TPP1 throughout the brain CLN2  mice. Importantly, intra venous administration of TPP1 with the peptide significantly reduced brain lysosomal storage, improved neurological functions and prolonged life expectancy. This simple "mix and inject" method can be applicable towards evaluation of enzyme replacement therapy to the brain in preclinical models and further exploration of its clinical potential is considered [199].





To date, treatment of sialidosis (mucolipidosis I), a lysosomal storage disorder, caused by deficiency of N-acetyl-α-nauraminidase-1 (NEU-1, also called sialidase), remains limited to supportive care only. No effective ERT could be developed, because the enzyme sialidase lacks mannose-6-phosphate and is unstable in the absence of its physiological chaperone PPCA (protective protein/cathepsin A), thus, it is prone to aggregation.
A therapeutic approach that may be potentially beneficial in treatment of sialidosis was recently proposed [201]. It was reported that the use a combination of two small pharmacological chaperones, i.e. MG132 and celastrol, leads to increase in the activity of defective sialidase enzyme in cell culture model. The effect was observed in fibroblasts from sialidosis patient as well as in sialidase-null fibroblasts with adenovirus-mediated expression of two different sialidase mutant variants (R225P and R341G) treated with MG132 or both MG132 and celastrol. Additionally, after MG132 treatment and MG132 in combination with celastrol, increased co-localisation of sialidase within lysosomal compartment was observed in cell cultures expressing mutant variants of the enzyme. Sialidosis fibroblasts also showed significant decrease of gangliosides’ levels upon treatment with celastrol alone or with combination of MG132 and celastrol. Results obtained with sialidosis cell cultures supported the hypothesis that MG132 and celastrol enhance refolding of mutant sialidase enzyme and promote its delivery to the lysosomes, suggesting a potential therapeutic role for these compounds in sialidosis [201]. 

Concluding remarks
	The results of experiments on the use of combined therapies for various LSDs, obtained by employing cell culture and animal models, as well as conducting clinical studies, revealed that simultaneous application of different approaches may be significantly more effective than each of them used alone. This provides a hope for development of therapies for many LSDs that might be of high efficacy. On the other hand, examples of unsuccessful use of some combinations indicate that proper choice of specific therapies and conditions of their applications are not trivial, and extensive studies on optimization of each particular combined treatment are necessary. The summary of studies on combined therapies for LSDs, performed to date, is presented in Tables 2 and 3. These tables indicate that significant work has been already conducted, but there are many fields to be investigated in the future. 
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Figure 1. Schematic summary of primary and secondary mechanisms of lysosomal storage diseases (LSDs).
 





Enzyme replacement therapy	ERT	Provision of active enzyme which is missing in patient’s cells
Bone marrow transplantation	BMT	Production of active enzyme by transplanted bone marrow cells
Hematopoietic stem cell transplantation	HSCT	Production of active enzyme by transplanted hematopoietic stem cells
Gene therapy	GT	Provision of fully active gene which is mutated in patient’s cells
Substrate reduction therapy	SRT	Inhibition of synthesis of the substrate which cannot be degraded in patient’s cells
Stop codon readthrough	SCR	Synthesis of full-length enzyme whose gene contains a non-sense mutation 
Small molecular chaperones (pharmaceutical chaperones)	SMC (PC)	Improvement of folding of the affected enzyme and prevention of its degradation
Anti-inflammatory agents 	AI	Decrease in the inflammation reactions
Antioxidants	AO	Inhibition of oxidative stress
Specific modifications of basic methods and other therapies: 
By-product replacement therapy	BRT	Replacement of missing or deficient products needed for normal cellular functioning
Chaperone-advanced replacement therapy	CHART	Combination of unique pharmacological chaperones with enzyme replacement therapies (ERTs) for LSDs
Immune modulation	IM	Modification of the immune response or the functioning of the immune system by the action of an immunomodulator
Immunosuppression	IMS	Inhibition or prevention of activity of the immune system by an immunosuppressive drug
Intra-cerebrospinal fluid enzyme replacement therapy	I-CSF	Provision of active enzyme which is missing in patient’s cells with intra-cerebrospinal fluid
Intracranial adeno-associated virus gene therapy	IC-AAV GT	Intracranial provision of fully active gene which is mutated in patient’s cells with the use of adeno-associated virus
Intravenous immunoglobulins	IVIG	Pooled, polyvalent, IgG antibodies extracted from the plasma of blood donors
Intravenous lentiviral gene therapy	IV-LENTI GT	Neonatal treatment with an intravenous injection of a lentiviral vector with fully active gene which is mutated in patient’s cells
Intravenous protein replacement 	IV-PR	Intravenous provision of active enzyme which is missing in patient’s cells
Nonviral gene therapy	NV GT	Provision of fully active gene which is mutated in patient’s cells with the use of minicircle DNA
Proteostasis regulators	PR	Modulation of proteome homeostasis
Short-acting beta 2-agonist 	SABA	Class of drugs that act on the beta2-adrenergic receptor, thereby causing smooth muscle relaxation, resulting in dilation of bronchial passages, vasodilation in muscle and liver, relaxation of uterine muscle, and release of insulin.






























Table 3. Methods and compositions for the treatment of lysosomal storage diseases (for abbreviations see Table 1).
Disease	Gene 	Locus	Storage material	Approved monotherapy	Tested combined therapies
Mucopolysaccharidoses - MPS I- MPS II- MPS IIIA- MPS IIIB- MPS IIIC- MPS IIID- MPS IVA- MPS IVB- MPS VI- MPS VII- MPS IX	IDUA IDSSGSHNAGLUHGSNATGNSGALNSGLB1ARSBGUSBHYAL1	4p16.3Xq2817q25.317q218p11.112q146q24.33p21.335q11-137q21.113p21.3	glycosaminoglycans (GAGs)	ERTBMTHSCT	ERT+ BMTERT+ HSCTERT+ SRTERT+ SCRERT+ SMCERT+ AIBMT+ GTOther:IV-PR + I-CSFNV GT + IMIC-AAV GT + IV-LENTI GT
Gaucher disease	GBA	1q21	GlucosylceramideGlucosylsphingosine	ERTSRT	ERT + SRTERT + PCPR + PC
Sialidosis (mucolipidosis I)	NEU1	6p21.33	Sialic acid (N-acetylneuraminic acid)	None 	PC + PC
Fabry disease (FD)	GLA	Xq22.1	Globotriaosylceramide (Gb3, GL-3)	ERT	ERT + PC (CHART)ERT + SRTERT + palliative care
Metachromatic leukodystrophy (MLD)	ARSA	22q13.33	Sulfogalactosylceramide	None 	GT + cell transplantation
Sandhoff disease	HEXB	5q13.3	GM2 ganglioside	None 	SRT +BMTSRT + AI AI+AODiet + SRTSRT + NSCT (neuronal stem cell transplantation)SRT + GT
Tay-Sachs disease (TSD)	HEXA	15q23	GM2 ganglioside	None	PC + PR
Niemann Pick disease type C (NPC1)	NPC1	18q11.2	GM2 gangliosideCholesterol	None	SRT + BRT (by-product replacement therapy)AI + AIAO+AOSRT + AI + curcuminGT (bone marrow-derived cells)GT (IV + IC injections)
Krabbe disease	GALC	14q31.3	Galactosylosphingosine (psychosine)	HSCT	BMT + ERTBMT + GTBMT + SRTBMT + AOSRT + AO
Pompe disease (Glycogen storage disease II, GSD II)	GAA	17q25.3	Glycogen	ERT	ERT + IMSERT + IMS + IVIGERT + TregERT + SABA ERT + PC CHARTERT + aerobic exercises
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Figure 1. Schematic summary of primary and secondary mechanisms of lysosomal storage diseases (LSDs).
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